Dermatology News and Research

Latest Dermatology News and Research

2010 ASCO Annual Meeting highlights new research findings on cancer

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

24 May 2010

Common myths about tanning and sun protection

Half the battle in knowing how to properly protect oneself from skin cancer is being able to separate fact from fiction. Unfortunately, some myths about tanning and sun protection are deep rooted and could mislead people into thinking that tanning is safe - when, in reality, nothing could be further from the truth.

24 May 2010

Information about tanning's damaging effect on appearance reduces sunbed use among young women

Information about the harm sunbeds can do to young people's appearance could make them less inclined to use the tanning devices, US scientists have found.

21 May 2010

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.

21 May 2010

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

21 May 2010

Invida Group completes joint venture agreement with MUGI

Invida Group, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has completed a joint venture agreement with the Indonesian pharmaceutical manufacturer MUGI.

20 May 2010

Ectoin shows positive effect on nanoparticle-induced lung inflammation: Study

bitop AG, which specializes in the development and marketing of Ectoin-containing medical devices, announces that Ectoin significantly reduces nanoparticle-induced inflammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease. It is the first time that Ectoin has been shown to have such an effect on nanoparticle-induced lung inflammation.

20 May 2010

Expert 'top tips' for management of childhood eczema

Several leading European dermatologists have launched guidance to help parents reduce the burden of eczema on children living with this disease. Experts from Denmark, France, Germany, Poland and Spain have come together to agree a consensus of 'top tips', which focus on avoiding situations that trigger painful flares and different ways to increase eczema 'flare-free' periods. The 'top tips', sponsored by Astellas Pharma Europe Ltd., are launched at the 10th European Society for Pediatric Dermatology Congress (ESPD), Switzerland.

20 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Allergan, Inc. today announced that the United States Food and Drug Administration has approved ZYMAXID (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms; Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumonia.

20 May 2010

Tanning an addiction among young women

Amber Peterson, 31, used to visit tanning booths every other day for 10 years until she was diagnosed with the deadliest form of skin cancer at age 26. After surgery to remove the melanoma and several lymph nodes, this blond-haired, blue-eyed, fair-skinned woman is currently cancer-free. She has since traded in tanning beds for self-tanner in a bottle.

19 May 2010

Warnings about a ruined appearance is best way to reduce tanning salon visits

What's the most effective way to convince young women to cut back on their indoor tanning, a habit that hikes their risk of melanoma, the deadliest form of skin cancer, by 75 percent? Warn them that it will cause leathery, wrinkled skin.

18 May 2010

Dynatronics third-quarter fiscal 2010 sales increase 7.9% to $8,235,060

Dynatronics Corporation today announced results for its fiscal third quarter ended March 31, 2010. Sales for the quarter increased 7.9 percent to $8,235,060, compared to $7,633,419 for the third quarter of the prior fiscal year. For the nine-month period ended March 31, 2010, sales increased 2.8 percent to $25,018,960, compared to $24,348,461 for the same period in the prior fiscal year.

18 May 2010

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

17 May 2010

Halozyme announces voluntary HYLENEX product recall

Halozyme Therapeutics, Inc. today announced that Halozyme and Baxter have confirmed the presence of small flake-like glass particles in a limited number of vials of HYLENEX® (hyaluronidase human injection) product at the Baxter manufacturing facility. Earlier today, Halozyme notified the U.S. Food and Drug Administration that it is voluntarily recalling affected lots of 150U HYLENEX product from distribution.

17 May 2010

Halozyme Therapeutics announces delivery of notice of breach to Baxter Healthcare

Halozyme Therapeutics, Inc. today announced the delivery of a notice of breach to Baxter Healthcare Corporation due to Baxter's failure to provide HYLENEX (hyaluronidase human injection) in accordance with the terms of the parties' existing development and supply contracts.

17 May 2010

Large number of people do not see health-care provider for skin cancer screening: Survey

Despite the fact that skin cancer is the only cancer that can be seen on the surface of the skin, a new survey by the American Academy of Dermatology reports that a large number of people are not taking the time to examine their skin for any changes that could be warning signs of skin cancer or seeing a health-care provider for a skin cancer screening.

17 May 2010

11 leading medical societies support Health Care Truth and Transparency Act of 2010

As the United States prepares to add 32 million more patients to the health care system through health care reform, 11 of the leading medical societies in the country joined together today to publicly support the introduction of the Health Care Truth and Transparency Act of 2010.

14 May 2010

FDA Advisory Committee planned to review Lux Biosciences' NDA for voclosporin

Isotechnika Pharma Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration is scheduled to review partner, Lux Biosciences', New Drug Application for voclosporin on June 28, 2010.

13 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Dermatology News and Research

Latest Dermatology News and Research

2010 ASCO Annual Meeting highlights new research findings on cancer

Common myths about tanning and sun protection

Information about tanning's damaging effect on appearance reduces sunbed use among young women

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Invida Group completes joint venture agreement with MUGI

Ectoin shows positive effect on nanoparticle-induced lung inflammation: Study

Expert 'top tips' for management of childhood eczema

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Tanning an addiction among young women

Warnings about a ruined appearance is best way to reduce tanning salon visits

Dynatronics third-quarter fiscal 2010 sales increase 7.9% to $8,235,060

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Halozyme announces voluntary HYLENEX product recall

Halozyme Therapeutics announces delivery of notice of breach to Baxter Healthcare

Large number of people do not see health-care provider for skin cancer screening: Survey

11 leading medical societies support Health Care Truth and Transparency Act of 2010

FDA Advisory Committee planned to review Lux Biosciences' NDA for voclosporin

Merck hosts R&D and Business Briefing

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dermatology News and Research

Latest Dermatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in